CN115136955A - 细胞冻存液及其制备方法和应用 - Google Patents
细胞冻存液及其制备方法和应用 Download PDFInfo
- Publication number
- CN115136955A CN115136955A CN202210928640.3A CN202210928640A CN115136955A CN 115136955 A CN115136955 A CN 115136955A CN 202210928640 A CN202210928640 A CN 202210928640A CN 115136955 A CN115136955 A CN 115136955A
- Authority
- CN
- China
- Prior art keywords
- cell
- cells
- car
- cryopreservation
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title abstract description 13
- 239000012595 freezing medium Substances 0.000 title abstract description 7
- 238000005138 cryopreservation Methods 0.000 claims abstract description 71
- 239000000243 solution Substances 0.000 claims abstract description 60
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 38
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims abstract description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 19
- 102000008100 Human Serum Albumin Human genes 0.000 claims abstract description 19
- 108091006905 Human Serum Albumin Proteins 0.000 claims abstract description 19
- 229940119744 dextran 40 Drugs 0.000 claims abstract description 17
- 229940093181 glucose injection Drugs 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 14
- 239000007788 liquid Substances 0.000 claims abstract description 13
- 239000011550 stock solution Substances 0.000 claims description 32
- 239000006285 cell suspension Substances 0.000 claims description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 229940090044 injection Drugs 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 238000004321 preservation Methods 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 abstract description 20
- 238000011084 recovery Methods 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 14
- 230000008569 process Effects 0.000 abstract description 6
- 230000005779 cell damage Effects 0.000 abstract description 5
- 208000037887 cell injury Diseases 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 150
- 230000008014 freezing Effects 0.000 description 36
- 238000007710 freezing Methods 0.000 description 35
- 241000699670 Mus sp. Species 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229920002307 Dextran Polymers 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000003223 protective agent Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000009776 industrial production Methods 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000005909 tumor killing Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000204031 Mycoplasma Species 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000003749 cleanliness Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000005917 in vivo anti-tumor Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000003058 plasma substitute Substances 0.000 description 2
- 238000007447 staining method Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000520272 Pantoea Species 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002338 cryopreservative effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940045426 kymriah Drugs 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 108010078373 tisagenlecleucel Proteins 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Environmental Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
检验项目 | 检验标准 |
外观 | 透明液体 |
无菌 | 阴性 |
支原体 | 阴性 |
内毒素 | <3.5EU/mL |
pH | 6.0-8.0 |
复苏后细胞活率 | 诺华配方冻存液 | 本申请实施例1冻存液 |
冻存液2-8℃存放1周 | 89.5%、88.9% | 96.6%、95.8% |
冻存液现用现配 | 89.0%、90.2% | 94.9%、96.3% |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210928640.3A CN115136955A (zh) | 2022-08-03 | 2022-08-03 | 细胞冻存液及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210928640.3A CN115136955A (zh) | 2022-08-03 | 2022-08-03 | 细胞冻存液及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115136955A true CN115136955A (zh) | 2022-10-04 |
Family
ID=83414028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210928640.3A Pending CN115136955A (zh) | 2022-08-03 | 2022-08-03 | 细胞冻存液及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115136955A (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103563888A (zh) * | 2013-10-31 | 2014-02-12 | 北京永泰免疫应用科技有限公司 | 细胞冻存液 |
CN105660606A (zh) * | 2016-03-10 | 2016-06-15 | 广州赛莱拉干细胞科技股份有限公司 | 一种细胞冻存液 |
CN108552160A (zh) * | 2018-05-04 | 2018-09-21 | 武汉波睿达生物科技有限公司 | 一种直接静脉回输的car-t细胞冻存液及其制备方法和应用 |
CN108721331A (zh) * | 2018-04-27 | 2018-11-02 | 上海恒润达生生物科技有限公司 | 一种嵌合抗原受体t细胞制剂及其低温保存制剂制备方法 |
CN108925548A (zh) * | 2017-05-24 | 2018-12-04 | 西比曼生物科技(香港)有限公司 | 一种冻存细胞制剂及细胞复苏方式 |
CN109526945A (zh) * | 2019-01-16 | 2019-03-29 | 深圳咖荻生物科技有限公司 | 冻存液及用于人体回输的car-t细胞冻存制剂 |
CN110959606A (zh) * | 2018-09-28 | 2020-04-07 | 上海细胞治疗集团有限公司 | 一种免疫效应细胞冻存液及其用途 |
US20210169069A1 (en) * | 2016-11-04 | 2021-06-10 | The University Of Tokyo | Solution for cryopreservation of animal cells or animal tissues, cryopreserved product, and cryopreservation method |
WO2022133061A1 (en) * | 2020-12-17 | 2022-06-23 | Artiva Biotherapeutics, Inc. | Infusion ready cryopreservation compositions |
-
2022
- 2022-08-03 CN CN202210928640.3A patent/CN115136955A/zh active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103563888A (zh) * | 2013-10-31 | 2014-02-12 | 北京永泰免疫应用科技有限公司 | 细胞冻存液 |
CN105660606A (zh) * | 2016-03-10 | 2016-06-15 | 广州赛莱拉干细胞科技股份有限公司 | 一种细胞冻存液 |
US20210169069A1 (en) * | 2016-11-04 | 2021-06-10 | The University Of Tokyo | Solution for cryopreservation of animal cells or animal tissues, cryopreserved product, and cryopreservation method |
CN108925548A (zh) * | 2017-05-24 | 2018-12-04 | 西比曼生物科技(香港)有限公司 | 一种冻存细胞制剂及细胞复苏方式 |
CN108721331A (zh) * | 2018-04-27 | 2018-11-02 | 上海恒润达生生物科技有限公司 | 一种嵌合抗原受体t细胞制剂及其低温保存制剂制备方法 |
CN108552160A (zh) * | 2018-05-04 | 2018-09-21 | 武汉波睿达生物科技有限公司 | 一种直接静脉回输的car-t细胞冻存液及其制备方法和应用 |
CN110959606A (zh) * | 2018-09-28 | 2020-04-07 | 上海细胞治疗集团有限公司 | 一种免疫效应细胞冻存液及其用途 |
CN109526945A (zh) * | 2019-01-16 | 2019-03-29 | 深圳咖荻生物科技有限公司 | 冻存液及用于人体回输的car-t细胞冻存制剂 |
WO2022133061A1 (en) * | 2020-12-17 | 2022-06-23 | Artiva Biotherapeutics, Inc. | Infusion ready cryopreservation compositions |
Non-Patent Citations (1)
Title |
---|
姬广超等: "临床用途细胞冻存保护液探索实验", 《中国医药生物技术》, vol. 16, no. 2, pages 158 - 160 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107148967B (zh) | 一种抗原特异性t淋巴细胞冻存液及其制备方法和应用 | |
CN104719282B (zh) | 一种外周血单个核细胞无血清冻存液及冻存方法 | |
RU2146088C1 (ru) | Концентрированный раствор для хранения в криогенных условиях (варианты), раствор для хранения в криогенных условиях, способ криогенного хранения клеток (варианты), способ криогенного хранения и регенерации жизнеспособных клеток, способ криогенного хранения, регенерации и терапевтического применения клеток | |
Hill et al. | Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease | |
CN103563888B (zh) | 细胞冻存液 | |
CN105076116B (zh) | 一种细胞冻存液及其应用与巨核祖细胞的冻存方法 | |
Buchanan et al. | Preservation of differentiation and clonogenic potential of human hematopoietic stem and progenitor cells during lyophilization and ambient storage | |
Rajan et al. | Development and application of cryoprotectants | |
JP2008531051A (ja) | すぐに利用できる末梢血由来の細胞物質を提供する方法およびその組成 | |
CN107809905A (zh) | 用于治疗目的的细胞的冷藏方法 | |
US20100004342A1 (en) | LFA-1 Inhibitors and Use Thereof | |
CN110100812A (zh) | 一种免疫细胞的冻存回输液、冻存方法及回输应用 | |
CN112998009A (zh) | Nk细胞冻存液及其制备方法和应用 | |
CN105941389A (zh) | 一种无动物源血清的细胞冻存液 | |
Landy et al. | An antibody-complement system in normal serum lethal to mouse tumor cells | |
Storb et al. | Rejection of marrow from DLA-identical canine littermates given transfusions before grafting: antigens involved are expressed on leukocytes and skin epithelial cells but not on platelets and red blood cells | |
CN114041456B (zh) | 一种临床级nk细胞冻存液及其使用方法 | |
CN115039763A (zh) | 一种免疫细胞冻存液 | |
CN105211052A (zh) | 一种培养后的nkt细胞的冻存液及其制备方法 | |
Morgan et al. | The effect of low temperature and storage on the viability and mouse strain specificity of ascitic tumor cells | |
US20230148586A1 (en) | Low-temperature storage of biological samples | |
US3852155A (en) | Cryopreservation of equine cell cultures | |
CN113100227A (zh) | 一种可直接输入人体的nk细胞运输液及其制备方法和应用 | |
CN115136955A (zh) | 细胞冻存液及其制备方法和应用 | |
CN107711823A (zh) | 一种常温保存的细胞冻存液及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240610 Address after: 518000 Room 201, building A, No. 1, Qian Wan Road, Qianhai Shenzhen Hong Kong cooperation zone, Shenzhen, Guangdong (Shenzhen Qianhai business secretary Co., Ltd.) Applicant after: Shenzhen Binhong Biotechnology Co.,Ltd. Country or region after: China Address before: 518000 Room 201, building A, 1 front Bay Road, Shenzhen Qianhai cooperation zone, Shenzhen, Guangdong Applicant before: SHENZHEN BINDEBIOTECH Co.,Ltd. Country or region before: China |